Samsung Biologics: Creation of a Holding Company to Split CDMO and Biosimilar Businesses

343 Views22 May 2025 16:29

On 22 May, Samsung Biologics (207940 KS) announced that that it plans to establish a new holding company called Samsung Bioepis Holdings through a spin-off.

What is covered in the Full Insight:

Introduction to Samsung Biologics' Spin-off
Financial Growth and Key Metrics
Impact of U.S. Drug Price Policies
Ownership and Shareholder Structure
Future Outlook and Challenges

Douglas Kim

SUMMARY

(Sign Up to Access)

Try Now

Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:

Unlock research summaries
Follow top, independent analysts
Receive personalised alerts
Access Analytics, Events and more

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

SMARTKARMA PREVIEW PASS

By signing up, you agree to our
Terms of Use and Privacy Policy.

Already have an account? Sign In Now

Full Insight

(Paid Plans Only, 10-minute read)

Discussions

(Paid Plans Only)

Price Chart(Sign Up to Access)

Insight Stream